|Bid||0.550 x 800|
|Ask||0.640 x 2200|
|Day's Range||0.493 - 0.580|
|52 Week Range||0.350 - 4.950|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of Ampio Pharmaceuticals Inc. (ampe) plunged 69% in morning trade Wednesady, to fall back below the $1 threshold for the first time in 10 months, after the biopharmaceutical company said the Food and Drug Administration said a current trial for a treatment of osteoarthritis of the knee did not support a biologics license application (BLA). The FDA said the that as a single trial, the AP-003-A trial on its own does not appear to provide sufficient evidence of effectiveness to support a BLA. The FDA recommended an additional randomized trial.
In this article, I’m going to take a look at Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
If you are a shareholder in Ampio Pharmaceuticals Inc’s (AMEX:AMPE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
Ampio Pharmaceuticals Inc (AMEX:AMPE), a US$233.14M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
Mike Macaluso is the CEO of Ampio Pharmaceuticals Inc (AMEX:AMPE), which has recently grown to a market capitalization of $220.23M. Understanding how CEOs are incentivised to run and grow theirRead More...
In this analysis, my focus will be on developing a perspective on Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...
Examining how Ampio Pharmaceuticals Inc (AMEX:AMPE) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...
Case in point: Ampio Pharmaceuticals Inc (NYSE:AMPE), whose shares are jumping nearly 50% in Thursday trading session. The biopharmaceutical company reported that its knee osteoarthritis drug Ampion met its primary endpoint in Phase 3 clinical trial. Specifically, 71% of Ampion treated patients met OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.